Evaxion’s AI Platform Hits 86% Precision, Extends Phase 2 Trial and Secures Cash into H2 2027
Evaxion’s AI-Immunology™ achieved 86% vaccine target recognition for cancer vaccine EVX-01, enabling presentation of three-year phase 2 data in H2 2026. It completed one-year extension of EVX-01 trial, unveiled AI-driven polio vaccine concepts with Gates Foundation, promoted Birgitte Rønø to CSO/COO and secured cash runway into H2 2027.
1. R&D Validation of AI-Immunology
Evaxion’s AI-Immunology™ platform delivered data showing 86% precision in selecting vaccine targets for EVX-01, marking one of the highest success rates reported in personalized cancer vaccines. New scalability data demonstrated the platform’s ability to identify novel glioblastoma targets, reinforcing its potential across multiple high-mutational-burden indications.
2. Phase 2 Trial Extension and Upcoming Data
The company completed a one-year extension of its phase 2 EVX-01 trial, with the last patient visit in April. This extension allows evaluation of EVX-01 as monotherapy in the third year and sets up presentation of three-year durability and efficacy data in the second half of 2026.
3. Strategic Partnerships, Leadership and Runway
Evaxion unveiled AI-driven design concepts for next-generation polio vaccines in collaboration with Gates Foundation, aiming to combine the strengths of existing inactivated and attenuated platforms. It promoted Birgitte Rønø to Chief Scientific and Operating Officer, elected Jens Bitsch-Nørhave to the board and maintained cash runway into H2 2027 to fund operations.